Extending in vivo half-life of therapeutic proteins (L-11944) .: NR16-182/2017E-PDF
“Post-translational modifications of therapeutic proteins are commonly made to improve their circulating half-life, thereby enhancing their efficiency. Numerous strategies have been employed towards this end, including covalent modification, such as through PEGylation, the chemical addition of chains of polyethylene glycol (PEG) to therapeutic proteins. However, PEGylation relies on chemical conjugation of PEG chains to free amino groups or engineered cysteine residues on the protein, which can lead to heterogeneously-modified proteins whose activity can be adversely affected. To address this, the NRC has developed a site-specific, two-step in vitro modification process whereby polysialic acid (PSA) is enzymatically added to existing glycans, resulting in proteins with greater stability, solubility and circulating half-life”--Highlights.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.847765&sl=0
| Department/Agency | National Research Council Canada. |
|---|---|
| Title | Extending in vivo half-life of therapeutic proteins (L-11944) . |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Format | Electronic |
| Electronic document | |
| Note(s) | Issued also in French under title: Accroître la demi-vie in vivo des protéines thérapeutiques (L-11944). Caption title. "December 2017." Issued also in print format. |
| Publishing information | [Ottawa] : National Research Council Canada, [2018] |
| Description | [1] p. |
| ISBN | 9780660240114 |
| Catalogue number |
|
| Subject terms | Recombinant proteins Protein engineering |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.- Date modified: